Cholesteryl ester transfer protein (CETP) inhibitors, such as anacetrapib, increase HDL cholesterol levels.56,57 The REVEAL trial demonstrated that treatment with anacetrapib reduced the risk of a composite cardiovascular disease endpoint, though the impact of CETP inhibition on ischemic stroke risk remains uncertain.57 To investigate this question, Georgakis et al. This evidence concerns the gene CETP and ischemic stroke.